Ironwood Pharmaceuticals Shares Outstanding 2009-2020 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2009 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
2010 90
2009 7
2008 7
2007 7
2006 6
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
2010-12-31 90
2010-09-30 98
2010-06-30 98
2010-03-31 64
2009-12-31 7
2009-09-30 7
2009-06-30 7
2009-03-31 7
2008-12-31
2008-09-30
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.844B $0.428B
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.223B 41.55
Takeda Pharmaceutical (TAK) Japan $56.214B 10.49
Astellas Pharma (ALPMY) Japan $26.631B 16.63
Eisai (ESALY) Japan $22.251B 19.39
UCB SA (UCBJF) Belgium $21.755B 0.00
Merck (MKGAF) Germany $20.537B 26.93
Catalent (CTLT) United States $15.834B 47.36
Grifols, S.A (GRFS) Spain $12.740B 14.59
Neurocrine Biosciences (NBIX) United States $8.870B 69.81
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $8.491B 0.00
IPSEN SA ADR (IPSEY) France $8.056B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.840B 12.66
Ionis Pharmaceuticals (IONS) United States $7.065B 69.22
STADA ARZNEIMI (STDAF) Germany $6.884B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $6.425B 0.00
Orion OYJ (ORINY) Finland $6.272B 21.76
United Therapeutics (UTHR) United States $5.895B 12.55
Evotec AG (EVTCY) Germany $4.984B 338.72
PTC Therapeutics (PTCT) United States $4.270B 0.00
Sage Therapeutics (SAGE) United States $3.856B 0.00
ChemoCentryx (CCXI) United States $3.817B 0.00
FibroGen (FGEN) United States $3.760B 0.00
Hypermarcas (HYPMY) Brazil $3.667B 13.49
Cronos Group (CRON) Canada $3.152B 0.00
Nektar Therapeutics (NKTR) United States $2.940B 0.00
Revolution Medicines (RVMD) United States $2.896B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.701B 13.79
Pacira BioSciences (PCRX) United States $2.632B 57.16
Corcept Therapeutics (CORT) United States $2.630B 25.44
Xencor (XNCR) United States $2.432B 0.00
Trillium Therapeutics (TRIL) Canada $2.027B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.922B 0.00
Translate Bio (TBIO) United States $1.651B 0.00
USANA Health Sciences (USNA) United States $1.582B 13.92
Heron Therapeutics (HRTX) United States $1.575B 0.00
Karyopharm Therapeutics (KPTI) United States $1.250B 0.00
Ocular Therapeutix (OCUL) United States $1.249B 0.00
Tilray (TLRY) Canada $1.207B 0.00
Zogenix (ZGNX) United States $1.193B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.184B 8.23
Endo (ENDP) Ireland $1.170B 1.78
Theravance Biopharma (TBPH) Cayman Islands $1.061B 0.00
Indivior (INVVY) United States $1.059B 13.13
ImmunoGen (IMGN) United States $1.022B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.942B 0.00
Vectura Group (VEGPF) United Kingdom $0.925B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.902B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.878B 0.00
VAXART, INC (VXRT) United States $0.874B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.827B 0.00
Esperion Therapeutics (ESPR) United States $0.789B 0.00
Radius Health (RDUS) United States $0.735B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.687B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.649B 33.87
Collegium Pharmaceutical (COLL) United States $0.639B 37.74
Chinook Therapeutics (KDNY) United States $0.589B 0.00
Aerie Pharmaceuticals (AERI) United States $0.581B 0.00
Ardelyx (ARDX) United States $0.569B 0.00
Organogenesis Holdings (ORGO) United States $0.555B 0.00
Siga Technologies (SIGA) United States $0.536B 15.06
Flexion Therapeutics (FLXN) United States $0.528B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.512B 0.00
Akebia Therapeutics (AKBA) United States $0.478B 0.00
Molecular Templates (MTEM) United States $0.447B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.440B 0.00
Innate Pharma SA (IPHYF) France $0.428B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.418B 0.00
Altimmune (ALT) United States $0.404B 0.00
TherapeuticsMD (TXMD) United States $0.402B 0.00
Profound Medical (PROF) Canada $0.391B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.379B 9.89
Harpoon Therapeutics (HARP) United States $0.379B 0.00
DURECT (DRRX) United States $0.376B 0.00
Concert Pharmaceuticals (CNCE) United States $0.349B 0.00
Calithera Biosciences (CALA) United States $0.346B 0.00
Rafael Holdings (RFL) United States $0.339B 0.00
KalVista Pharmaceuticals (KALV) United States $0.335B 0.00
Redhill Biopharma (RDHL) Israel $0.331B 0.00
MEI Pharma (MEIP) United States $0.324B 0.00
CASI Pharmaceuticals (CASI) United States $0.309B 0.00
Summit Therapeutics (SMMT) United States $0.303B 0.00
Menlo Therapeutics (VYNE) United States $0.285B 0.00
Jounce Therapeutics (JNCE) United States $0.285B 0.00
CTI BioPharma (CTIC) United States $0.266B 0.00
IMV INC (IMV) Canada $0.260B 0.00
Lannett Co Inc (LCI) United States $0.256B 6.77
Nature's Sunshine Products (NATR) United States $0.244B 15.73
Aquestive Therapeutics (AQST) United States $0.237B 0.00
Alpine Immune Sciences (ALPN) United States $0.232B 0.00
Otonomy (OTIC) United States $0.217B 0.00
Xeris Pharmaceuticals (XERS) United States $0.214B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.213B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.212B 0.00
OptiNose (OPTN) United States $0.211B 0.00
Heat Biologics (HTBX) United States $0.179B 0.00
Taiwan Liposome (TLC) Taiwan $0.161B 0.00
Champions Oncology (CSBR) United States $0.145B 0.00
Aclaris Therapeutics (ACRS) United States $0.143B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.136B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.136B 0.00
Infinity Pharmaceuticals (INFI) United States $0.128B 0.00
Ayala Pharmaceuticals (AYLA) Israel $0.125B 0.00
ProPhase Labs (PRPH) United States $0.122B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.112B 0.00
Lipocine (LPCN) United States $0.105B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.103B 0.00
MediWound (MDWD) Israel $0.102B 0.00
India Globalization Capital (IGC) United States $0.095B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.090B 0.00
Biomerica (BMRA) United States $0.082B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.082B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.081B 0.00
Hemispherx BioPharma (AIM) United States $0.075B 0.00
KemPharm (KMPH) United States $0.073B 0.00
SCYNEXIS (SCYX) United States $0.073B 0.00
Novan (NOVN) United States $0.073B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.069B 0.00
ElectroCore (ECOR) United States $0.068B 0.00
AgeX Therapeutics (AGE) United States $0.067B 0.00
Nutriband (NTRB) United States $0.066B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.065B 0.00
Natural Alternatives (NAII) United States $0.065B 124.61
CV Sciences (CVSI) United States $0.063B 0.00
GTx (ONCT) United States $0.062B 0.00
Recro Pharma (REPH) United States $0.057B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.055B 0.00
Onconova Therapeutics (ONTX) United States $0.054B 0.00
Addex Therapeutics (ADXN) Switzerland $0.054B 0.00
Forward Pharma (FWP) Denmark $0.048B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.045B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.045B 22.77
Adamis Pharmaceuticals (ADMP) United States $0.039B 0.00
Mannatechorporated (MTEX) United States $0.039B 5.68
Vical (BBI) United States $0.036B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.035B 0.00
IsoRay (ISR) United States $0.033B 0.00
Iterum Therapeutics (ITRM) Ireland $0.031B 0.00
Can-Fite Biopharma (CANF) Israel $0.029B 0.00
PolarityTE (PTE) United States $0.028B 0.00
Neos Therapeutics (NEOS) United States $0.028B 0.00
Jaguar Animal Health (JAGX) United States $0.028B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.026B 0.00
Regulus Therapeutics (RGLS) United States $0.025B 0.00
Midatech Pharma (MTP) United Kingdom $0.023B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.019B 0.00
Cyanotech (CYAN) United States $0.018B 28.80
Hancock Jaffe Laboratories (HJLI) United States $0.017B 0.00
Bio-Path Holdings (BPTH) United States $0.016B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.015B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.014B 0.00
RXi Pharmaceuticals (PHIO) United States $0.014B 0.00
Flex Pharma (SLRX) United States $0.014B 0.00
Shineco (TYHT) China $0.011B 0.00
China SXT Pharmaceuticals (SXTC) China $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.010B 0.00
JanOne (JAN) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.007B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00
Sundial Growers (SNDL) Canada $0.000B 0.00